Growth hormone and metabolism

Diabetes/Metabolism Reviews

Volumn 4, Issue 4, 1988, Pages 391-414

  Press, Martin ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN;

CARBOHYDRATE METABOLISM; DIABETES MELLITUS; HORMONE RELEASE; HUMAN; PROTEIN METABOLISM; REVIEW;

ANIMAL; GROWTH HORMONE; HUMAN; METABOLISM;

EID: 0023933866     PISSN: 07424221     EISSN: 10990895     Source Type: Journal    
DOI: 10.1002/dmr.5610040406     Document Type: Article

References (298)

1. Structure, expression and evolution of growth hormone genes
2. The isolation of pituitary growth hormone
3. Isolation and properties of the anterior hypophyseal growth hormone
4. Preparation and properties of growth hormone from human and monkey pituitary glands
5. The molecular nature of circulating growth hormone in normal and acromegalic man: Evidence for a principal and minor monomeric forms
6. The genes for growth hormone and chorionic somatomammotropin are on the long arm of human chromosome 17 in region q21 qter
7. Genes for growth hormone, chorionic somatomammotropin and growth hormone‐like gene on chromosome 17 in humans
8. The human growth hormone gene family: Nucleotide sequences show recent divergence and predict a new polypeptide hormone
9. Growth hormone: Deletions in the protein and nitrons in the gene
10. Human growth hormone DNA sequence and mRNA structure: Possible alternative splicing
11. Properties of human growth hormone polypeptides: Purified from pituitary extracts and synthesized in monkey kidney cells and bacteria
12. The 20,000‐dalton structural variant of human growth hormone: Lack of some early insulin‐like effects
13. Hyperglycemic activity of the 20,000‐dalton variant of human growth hormone
14. Variants of growth hormone and prolactin and their posttranslational modifications
15. Multiple forms of human growth hormone
16. Characterization of growth hormone of different molecular weights in rat, dog, and human pituitaries
17. Studies on “big” growth hormone from human plasma and pituitary
18. Studies of the composition and radioreceptor activity of “big” and “little” human growth hormone
19. Studies on bioassayable growth hormone‐like activity of plasma
20. A growth hormone binding protein in normal human serum
21. Studies on the heterogeneity and serum binding of human growth hormone
22. Affinity purification and structural characterization of a specific binding protein for human growth hormone in human serum
23. A specific growth hormone‐binding protein in human plasma: Initial characterization
24. Human growth hormone: A complex of proteins
25. Structural variants of human growth hormone: Biochemical, genetic and clinical aspects
26. The multivalent nature of growth hormone
27. The effect of the anterior lobe administered intraperitoneally upon growth, maturity and oestrus cycles of the rat
28. Studies in acromegaly. VIII. Experimental canine acromegaly produced by injection of anterior lobe pituitary extract
29. Effects of growth hormone in normal and hypophysectomized rhesus monkeys
30. Some physiologic effects of primate pituitary growth hormone preparations in the hypophysectomized rhesus monkey
31. The physiology of growth hormone with particular reference to its action in the rhesus monkey and the “species specificity” problem
32. Metabolic effects of human and monkey growth hormone in man
33. Human growth hormone
34. Growth hormone and insulin binding to human liver
35. Reactivity of nonprimate growth hormones and prolactins with human growth hormone receptors on cultured human lymphocytes
36. Studies of insulin, growth hormone and prolactin binding: Tissue distribution, species variation and characterization
37. Purification and partial characterization of a nonprimate growth hormone receptor
38. Structures of the somatotropin receptor and prolactin receptor on rat hepatocytes characterized by affinity labelling
39. Structural studies of the growth hormone receptor by affinity labelling
40. Monoclonal antibodies to the rabbit liver growth hormone receptor: Production and characterization
41. Evidence from the use of monoclonal antibody probes for structural heterogeneity of the growth hormone receptor
42. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro
43. The somatomedins
44. Somatomedins
45. Actions of insulin‐like growth factors
46. Hepatic clearance of human growth hormone
47. Somatomedin generation by perfused livers
48. Comparison of somatomedin activity in perfusates of normal and hypophysectomized rat livers with and without added growth hormone
49. The liver as a source of somatomedin: An in vivo study in the dog
50. The effects of insulin and growth hormone on the release of somatomedin by the isolated rat liver
51. Current concepts of somatomedin and the biologically related growth factors
52. Sulfation factor regulation of skeletal growth. A stable mechanism dependent on intermittent growth hormone secretion
53. Insulin‐like growth factor I stimulates growth in hypophysectomized rats
54. Comparison of in vivo effects of insulin‐like growth factors I and II and of growth hormone in hypophysectomized rats
55. Growth hormone stimulates longitudinal bone growth directly
56. Effects of local administration of GH and IGF‐I on longitudinal bone growth in rats
57. Evidence suggesting that the direct growth‐promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin
58. Insulin‐like growth factors I and II; Some biological actions and receptor binding characteristics of two purified constituents of nonsuppressible insulin‐like activity of human serum
59. Serum NSILA and IGF: News and riddles
60. Insulin‐like growth factors stimulate synthesis of nucleic acids and glycogen in cultured calvaria cells
61. Dual control of cell growth by somatomedins and platelet‐derived growth factor
62. Antibody‐suppressible and nonsuppressible insulin‐like activities in human serum and their physiologic significance. An insulin assay with adipose tissue of increased precision and specificity
63. The purification and partial characterization of an insulin‐like protein from human serum
64. Primary structure of human insulin‐like growth factor II
65. The insulin‐like growth factors of human serum: Chemical and biological characterization and aspects of their possible physiological role
66. Effects of insulin‐like growth factors on chick embryo hepatocytes
67. Plasma forms of somatomedin and the binding protein phenomenon
68. Acute metabolic effects and half‐lives of intravenously administered insulin‐like growth factors I and II in normal and hypophysectomized rats
69. NSILA‐carrier protein abolishes the action of nonsuppressible insulin‐like activity (NSILA‐s) on perfused rat heart
70. Inhibition of the action of nonsuppressible insulin‐like activity on isolated rat fat cells by binding to its carrier protein
71. Recent advances in the biochemistry and physiology of the insulin‐like growth factor/somatomedin family
72. Evidence for a biologically active, carrier‐bound form of nonsuppressible insulin‐like activity in human serum
73. Risk of hypoglycaemia with alternate day growth hormone injections
74. Studies on human growth hormone. II. The physiological disposition and metabolic fate of human growth hormone in man
75. Kinetics of the somatomedin C/insulin‐like growth factor I response to exogenous growth hormone in growth hormone deficient children
76. Importance of raised growth hormone levels in mediating the metabolic derangements of diabetes
77. Hypoglycemia associated with non‐islet‐cell tumor and insulin‐like growth factors
78. Is extrapan‐creatic tumor hypoglycemia associated with elevated levels of insulin‐like growth factor II?
79. Measurement of insulin‐like growth factor II by a specific radioreceptor assay in serum of normal individuals, patients with abnormal growth hormone secretion, and patients with tumor‐associated hypoglycemia
80. Insulin‐like growth factors in patients with non‐islet cell tumors and hypoglycemia
81. In vitro stimulation of leucine incorporation into muscle and cartilage protein by a serum fraction with sulfation factor activity: Differentiation of effects from those of growth hormone and insulin
82. Effects of human somatomedin preparations on membrane transport and protein synthesis in the isolated rat diaphragm
83. Estimation of somatomedin‐C levels in normals and patients with pituitary disease by radioimmunoassay
84. Serum levels of insulin‐like growth factor and its carrier protein in various metabolic disorders
85. Dietary components that regulate serum somatomedin C concentration in humans
86. Insulin‐like growth factors in the fed and fasted states
87. The relation between the growth and diabetogenic effects of the so‐called growth hormone of the anterior pituitary
88. Diabetogenic polypeptide from human pituitaries similar to that excreted by proteinuric diabetic patients
89. Human pituitary tissue secretes a potent growth factor for chondrocyte proliferation
90. Growth hormone and lipolysis: A reevaluation
91. Both human pituitary growth hormone and recombinant DNA‐derived human growth hormone cause insulin resistance at a post‐receptor site
92. A hybrid non‐covalent complex of fragments of porcine and human growth hormone with diabetogenic activity
93. Biological activity of bacterial derived human growth hormone in adipose tissue of hypophysectomized rats
94. Biosynthetic 20‐kilo dalton methionyl‐human growth hormone has diasetogenic and insulin‐like activities
95. Recombinant deoxyribonucleic acid‐derived 22K‐ and 20K‐ human growth hormone generate equivalent diabetogenic effects during chronic infusion in dogs
96. Rapid effects of growth hormone on amino acid transport and protein synthesis
97. Early and late effects of growth hormone on transport of amino acids and monosaccharides in the isolated rat diaphragm
98. In vitro actions of growth hormone on amino acid transport and protein synthesis
99. Separation of the effects of growth hormone on muscle amino acid transport and protein synthesis
100. Antilipolytic effects of growth hormone
101. Studies on the mechanism of the antilipolytic effects of growth hormone
102. Comparison of several insulin‐like effects of growth hormone
103. Acute reduction of plasma non esterified fatty acids by growth hormone in hypophysectomized and Houssay rats
104. The anti‐lipolytic, insulin‐like effect of growth hormone is caused by a net decrease of hormone‐sensitive lipase phosphorylation
105. Early and late effects of growth hormone on the metabolism of glucose in adipose tissue
106. Effects of growth hormone on isolated adipose tissue
107. The effects of growth hormone on carbohydrate and lipid metabolism in the dog
108. Effects of insulin and growth hormone on the flux rates of plasma glucose and plasma free fatty acids in man
109. Acute metabolic effects of human growth hormone
110. Early insulin synergistic activity of growth hormone
111. Effects of growth hormone on glucose utilization in diaphragm muscle in the absence of increased lipolysis
112. Growth hormone and the metabolism of carbohydrate and lipid in adipose tissue
113. Effects of nutritional status and the pituitary on the acute plasma free fatty acid and glucose responses of rats to growth hormone administration
114. Some effects of purified pituitary growth hormone on carbohydrate metabolism in the rat
115. Early and late effects of growth hormone on the metabolism of glucose in adipose tissue
116. Hourly variations in plasma concentrations of growth hormone and insulin and in amino acid uptake and incorporation into protein in diaphragm muscle of the rat
117. Rapid modulation of protein synthesis in normal rats by specific neutralization and replacement of growth hormone
118. Influence of growth hormone on splanchnic glucose production in man
119. Physiologic concentrations of growth hormone exert insulin‐like and insulin antagonistic effects on both hepatic and extra‐hepatic tissues in man
120. The effect of growth hormone on glucose metabolism and insulin secretion in man
121. Roles of insulin and growth hormone based on studies of forearm metabolism in man
122. The effect of synthetic fragment 31–44 of human growth hormone on glucose uptake by isolated adipose tissue
123. Transmission of conformational change in insulin
124. Regulation of insulin secretion studied with pieces of rabbit pancreas incubated in vitro
125. Direct stimulation by growth hormone of glucagon and insulin release from isolated rat pancreas
126. Effect of growth hormone on acute glucagon and insulin release
127. Acute suppressive effect of human growth hormone on basal insulin secretion in man
128. Acute suppressive effect of human growth hormone on insulin release induced by glucagon and tolbutamide in man
129. On the diabetogenic effect of growth hormone in man: Effects of growth hormone on glucagon and insulin secretion
130. Insulin‐like and diabetogenic effects of growth hormone in healthy subjects, diabetics and low insulin responders
131. Correlative studies of growth hormone and insulin plasma concentrations with metabolic abnormalities in acromegaly
132. Plasma insulin response to sustained hyperglycemia induced by glucose infusion in human subjects
133. Influence of growth hormone on insulin secretion: Studies of growth hormone deficient subjects
134. The distribution of radioactivity in the tissues of the rat after the administration of radioactive growth hormone preparations
135. Effects of growth hormone, prolactin, and placental lactogen on insulin content and release, and deoxyribonucleic acid synthesis in cultured pancreatic islets
136. Growth hormone stimulates islet B‐cell replication in neonatal rat pancreatic monolayer cultures
137. Anabolic effects of human growth hormone and high caloric feedings following thermal injury
138. Metabolic effects of acute and prolonged growth hormone excess in normal and insulin‐deficient man
139. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization
140. Comparative rapidity of response of height, limb muscle and limb fat to treatment with human growth hormone in patients with and without growth hormone deficiency
141. Muscle and liver cell growth: Role of hormone and nutritional factors
142. Studies in the physiological properties of the growth‐promoting extracts of the anterior hypophysis
143. In vitro effects of growth hormone on the number and activity of ribosomes engaged in protein synthesis in the isolated rat diaphragm
144. In vitro stimulation of leucine incorporation into muscle and cartilage protein by a serum fraction with sulfation factor activity: Differentiation of effects from those of growth hormone and insulin
145. The biology of growth hormone
146. Relation of purified pituitary growth hormone and insulin in regulation of nitrogen balance
147. Insulin and protein synthesis
148. Analysis of refractoriness to the effects of growth hormone on amino acid transport and protein synthesis in diaphragms of young normal rats
149. Effects of growth hormone on protein and carbohydrate metabolism
150. Physiological and clinical studies of GRF and GH
151. Hormone‐fuel interrelationships during fasting
152. Metabolic response to human growth hormone during prolonged starvation
153. Growth hormone administration conserves lean body mass during dietary restriction in obese subjects
154. Enzyme regulation in gluconeogenesis and lipogenesis. Relationship of protein synthesis and cyclic AMP to lipolytic action of growth hormone and glucocorticoids
155. Acute reduction of plasma nonesterified fatty acid by growth hormone in hypophysectomized and Houssay rats
156. Role of lipolytic and glucocorticoid hormones in the development of diabetic ketosis
157. The effect of growth hormone on the metabolism of lipids and on urea formation by the perfused rat liver
158. The effects of growth hormone on carbohydrate and lipid metabolism
159. The influence of hypophysectomy and of growth hormone administration on the oxidation of palmitate‐1–14C by the unanaesthetized rat
160. Effect of growth hormone on plasma fatty acids
161. The regulation of plasma ketone body concentration by counterregulatory hormones in man
162. Importance of pituitary hormones in aetiology of diabetic ketoacidosis
163. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism
164. Pituitary growth hormone essential for regulation of serum cholesterol
165. Studies of hyperlipidemia in the HGH‐deficient state
166. Familial combined hyperlipoproteinemia. Evidence for a role of growth hormone deficiency in affecting its manifestation
167. Serum cholesterol and triglycerides in children with growth hormone deficiency
168. Effect of subacute administration of human growth hormone on various serum lipid and hormone levels of hypercholesterolemic and normocholesterolemic subjects
169. Absence of an effect of chronic administration of growth hormone on serum lipids
170. Growth hormone in the regulation of hyperlipidemia
171. Effect of thyroxine and growth hormone on the hypercholesterolemia of growth hormone deficiency
172. Effect of growth hormone replacement on development of hypothyroidism and hyperlipemia
173. Xanthoma accompanied by hypercholesterolemia occurring in an otherwise normal individual and in an individual with acromegaly and diabetes
174. A study in the pathogenesis of hyperlipemia in a patient with acromegaly and diabetes mellitus
175. Absence of hyperlipidemia in acromegaly
176. The hypophysis and metabolism
177. An Argentine trail of hypophysial research
178. Differentiation of growth hormone from the pituitary factor which produces diabetes
179. The growth hormone and diabetes
180. “Growth” and the diabetogenic action of anterior pituitary preparations
181. “Growth” and the diabetogenic action of anterior pituitary preparations. II. Growth and experimental insulin‐insensitive diabetes
182. The pituitary gland and carbohydrate metabolism
183. Permanent experimental diabetes produced by pituitary (anterior lobe) injections
184. Influence of fasting on changes in glucose metabolism induced by growth hormone injection in the normal dog
185. Effect of hypophysectomy on liver enzymes involved in glycogenolysis and in glucogenesis
186. The hormonal control of hepatic gluconeogenesis
187. Effects of hypophysectomy on amino acid metabolism and gluconeogenesis in the perfused rat liver
188. Histology of diabetes induced in dogs by injection of anterior pituitary extracts
189. Human growth hormone as a regulator of blood glucose concentration and as a diabetogenic substance
190. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment
191. Pharmacokinetics and pharmacodynamics
192. The effect of human growth hormone in man
193. Abnormalities in carbohydrate tolerance associated with elevated plasma non‐esterified fatty acids
194. The growth‐promoting and anti‐insulin actions of somatotropin
195. The diabetogenic action of human growth hormone: Glucose‐fatty acid interrelationships
196. Effect of growth hormone on oral glucose tolerance and circulating metabolic fuels in man
197. Acute effects of exogenous growth hormone in man: Time‐ and dose‐bound modification of glucose tolerance and glucose‐induced insulin release
198. Hormonal genesis of glucose intolerance following hypoglycemia
199. The effect of hypoglycemia on oral glucose tolerance in normal subjects and patients with pituitary and adrenal disorders
200. Influence of physiologic fluctuations in plasma growth hormone on glucose tolerance
201. Effect of human growth hormone in hypophysectomized diabetic subjects
202. Effect of growth hormone in hypophysectomized diabetic subjects
203. Effect of insulin on growth hormone induced metabolic derangements in diabetes
204. Profiles of metabolic control in diabetic children–Frequency of asymptomatic nocturnal hypoglycemia
205. In search of the Somogyi effect
206. Pathogenesis of the dawn phenomenon in patients with insulin‐dependent diabetes mellitus
207. The “dawn phenomenon”–A common occurrence in both non‐insulin dependent and insulin‐dependent diabetes mellitus
208. Glucose counter‐regulation and waning of insulin in the Somogyi phenomenon (post‐hypoglycemic hyperglycemia)
209. Diabetes, diabetic angiopathy and growth hormone
210. The pathogenesis of diabetic angiopathy and growth hormone
211. Growth hormone's role in diabetic microangiopathy
212. Severe retinopathy and mild carbohydrate intolerance: Possible role of insulin deficiency and elevated circulating growth hormone
213. Insulin‐like growth factors: Studies in diabetes with and without retinopathy
214. The physiology of growth hormone secretion
215. Absent sleep peak of growth hormone release in blind subjects: Correlation with sleep EEG stages
216. Physiological roles of somatocrinin and somatostatin in the regulation of growth hormone secretion
217. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
218. The effects of growth hormone releasing peptides on growth hormone secretion in perfused pituitary cells of adult male rats
219. 2 and GRF‐40
220. Distribution of immunoreactive growth hormone releasing hormone in the human brain and intestine and its production by tumors
221. Stimulation by food of peripheral plasma immunoreactive growth hormone releasing factor
222. Human pancreatic growth hormone releasing factor selectively stimulates growth hormone secretion in man
223. Inhibition of endogenous growth hormone secretion by exogenous growth hormone infusion in the rhesus monkey
224. The effect of administration of human growth hormone on the plasma growth hormone, cortisol, glucose, and free fatty acid response to insulin: Evidence for growth hormone autoregulation in man
225. Regulation of growth hormone release: Evidence against negative feedback in rat pituitary cells
226. Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution
227. Somatomedin‐C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary
228. Inhibition by somatomedins of growth hormone secretion stimulated by hypothalamic growth hormone releasing factor
229. Effects of insulin‐like growth factors on adult male rat pituitary function in tissue culture
230. Exogenous growth hormone inhibits growth hormone releasing factor‐induced growth hormone secretion in normal men
231. Suppression of the growth hormone response to clonidine and growth hormone releasing hormone by exogenous growth hormone
232. Hypoglycemia: A potent stimulus to secretion of growth hormone
233. The influence of blood glucose on the plasma concentration of growth hormone
234. The location of the chemoreceptor controlling growth hormone secretion during hypoglycemia in primates
235. Secretion of human growth hormone: Physiologic and experimental modification
236. Effect of a small decrease in blood glucose on plasma growth hormone and urinary excretion of catecholamines in man
237. Lack of relation between plasma growth hormone levels and small decrements in blood sugar
238. Rate of glucose fall does not affect counterregulatory hormone responses to hypoglycemia in normal and diabetic humans
239. Hypoglycemic threshold for human growth hormone release
240. Growth hormone release by glucagon
241. The regulation of growth hormone secretion
242. Human growth hormone release in sleep: Non‐suppression by acute hyperglycemia
243. Pituitary response to growth hormone releasing factor in diabetes: Failure of glucose‐mediated suppression
244. The effect of plasma glucose on the growth hormone response to growth hormone releasing factor in normal subjects
245. Oral glucose inhibits growth hormone secretion induced by human pancreatic hormone releasing factor 1–44 in normal man
246. Insulin suppresses growth hormone secretion by rat pituitary cells
247. Effects of insulin on rat anterior pituitary cells: Inhibition of growth hormone secretion and mRNA levels
248. Evidence for a central abnormality in the regulation of growth hormone secretion in insulin‐dependent diabetes
249. Effects of human growth hormone in elderly males
250. Abnormalities of growth hormone regulation in acute intermittent porphyria
251. Acute intermittent porphyria. A clinical and biochemical study of 46 patients
252. Serum glucose, insulin and growth hormone in chronic hepatic cirrhosis
253. Acute metabolic responses to myocardial infarction. Changes in glucose utilization and secretion of insulin and growth hormone
254. Serum growth hormone and glucose intolerance in renal failure
255. Plasma insulin and growth hormone levels in obesity and diabetes
256. Glucose counter‐regulation in man
257. Plasma growth hormone response to intravenous administration of amino acids
258. Effect of arginine or serum levels of human growth hormone
259. Arginine initiated release of human growth hormone. Factors modifying the response in normal man
260. Effect of food intake on growth hormone level
261. Patterns of hormonal release after glucose, protein and glucose plus protein
262. Effect of the administration of nicotinic acid or salicylate on plasma growth hormone concentrations
263. Effect of lipid and ketone infusions on insulin‐induced growth hormone elevations in rhesus monkeys
264. Inhibition of sleep related growth hormone release by elevated free fatty acids
265. The effect of free fatty acids on growth hormone releasing hormone mediated growth hormone secretion in man
266. Studies on growth hormone secretion in protein‐calorie malnutrition
267. Growth hormone and kwashiorkor
268. Impaired growth hormone responses to growth hormone releasing factor in obesity: A pituitary defect reversed with weight reduction
269. High 24 hour level of serum growth hormone in juvenile diabetics
270. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics
271. Diurnal growth hormone and glucose abnormalities in unstable diabetics: Studies of ambulatory fed subjects during continuous blood glucose analysis
272. Integrated concentration of growth hormone in juvenile‐onset diabetes
273. Growth hormone secretion in response to arginine infusion in normal and diabetic subjects: Relationship to blood glucose levels
274. Abnormal growth hormone response to ingestion of glucose in juvenile diabetics
275. Abnormal serum growth hormone response to exercise in juvenile diabetics
276. Deranged alpha‐adrenergic regulation of growth hormone secretion in poorly controlled diabetes: Reversal of the exaggerated response to clonidine after continuous subcutaneous insulin infusion
277. Characteristics of growth hormone secretion in clinically stable diabetes
278. Metabolic clearance rate of growth hormone in juvenile diabetes mellitus
279. Daily production and metabolic clearance of growth hormone in juvenile diabetes mellitus
280. Somatomedin activity and diabetic control in children with insulin‐dependent diabetes
281. Growth hormone and somatomedin in insulin‐dependent diabetes mellitus
282. Effect of diabetes and its control on insulin‐like growth factors in the young subject with type I diabetes
283. Impaired somatomedin generation test in children with insulin‐dependent diabetes mellitus
284. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes
285. Defective glucose counterregulation after strict glycemic control of insulin‐dependent diabetes mellitus
286. Intensive insulin therapy lowers glucose thresholds for counterregulation: A risk factor for hypoglycemia in diabetes
287. Stimulation of counterregulatory hormonal responses in diabetic man by a fall in glucose concentration
288. Growth hormone and cortisol responses to insulin infusion in patients with diabetes mellitus
289. Growth hormone response to hyper‐insulinaemia in insulin‐dependent diabetes: Comparison of patients with and without retinopathy
290. No evidence for increased growth hormone responses to growth hormone releasing hormone in patients with diabetic retinopathy
291. Changes in plasma growth hormone in diabetic and non‐diabetic subjects during the glucose clamp
292. Impaired growth hormone response to human pancreatic growth hormone releasing factor (GRF 1–44) in type 2 (non‐insulin dependent) diabetes